Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays.

Vandana BalodaErin K McCrearyBreana K GoscickiMichael R ShurinSarah E Wheeler

Published in: American journal of clinical pathology (2022)

This study indicates that T + C at pharmacologic Cmax is unlikely to interfere with SPE, IFE, sFLC, or IgG1 analyses when spiked into patient serum samples, but further evaluation of recently injected patients may be warranted.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
ms ms
prognostic factors
high throughput
mass spectrometry
patient reported